Remove Botox Remove Cosmetics Remove Licensing
article thumbnail

Aesthetic Alchemy: “Artistry of Medical Aesthetic Procedures”

Roots Analysis

The treatments / products provided by medical aesthetics companies used for facial aesthetic procedures have been mentioned below: Botulinum toxin: It is a toxin produced by a bacterium, Clostridium botulinum , commonly referred to as Botox. Tattoo Removal: It is a cosmetic procedure that involves removing ink from the top layer of the skin.

Filler 40
article thumbnail

Medical Aesthetics: “Redefining Beauty through Medical Expertise”

Roots Analysis

Medical aesthetics is a growing area of modern medicine that focuses on improving the cosmetic appearance of an individual through various medical treatments. However, Botulinum toxin was the real game-changer when it was approved for cosmetic use by the FDA in 2002.

Filler 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

The Pharma Data

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. Global Botox Cosmetic net revenues were $493 million , an increase of 9.1 Global Botox Therapeutic net revenues were $567 million , a decrease of 1.0 Botox Cosmetic*.

Botox 52
article thumbnail

AbbVie Reports First-Quarter 2021 Financial Results

The Pharma Data

Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 Botox Cosmetic*. Botox Therapeutic*. Global net revenues from the aesthetics portfolio were $1.141 billion , an increase of 34.9 Aesthetics. Neuroscience.

Botox 40
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

percent increase since 2021, predominantly due to Botox sales for therapeutic uses. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment.

Sales 85